Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation

Kishor K. Bhakat, Shiladitya Sengupta, Victor F. Adeniyi, Shrabasti Roychoudhury, Somsubhra Nath, Larry J. Bellot, Dan Feng, Anil K. Mantha, Mala Sinha, Suimin Qiu, Bruce A. Luxon

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Mammalian apurinic/apyrimidinic (AP) endonuclease 1 (APE1), a ubiquitous and multifunctional protein, plays an essential role in the repair of both endogenous and drug-induced DNA damages in the genome. Unlike its E.coli counterpart Xth, mammalian APE1 has a unique N-terminal domain and possesses both DNA damage repair and transcriptional regulatory functions. Although the overexpression of APE1 in diverse cancer types and the association of APE1 expression with chemotherapy resistance and poor prognosis are well documented, the cellular and molecular mechanisms that alter APE1 functions during tumorigenesis are largely unknown. Here, we show the presence of full-length APE1 and N-terminal truncated isoforms of APE1 in tumor tissue samples of various cancer types. However, primary tumor tissue has higher levels of acetylated APE1 (AcAPE1) as well as full-length APE1 compared to adjacent non-tumor tissue. We found that APE1 is proteolytically cleaved by an unknown serine protease at its N-terminus following residue lysine (Lys) Lys6 and/or Lys7 and after Lys27 and Lys31 or Lys32. Acetylation of these Lys residues in APE1 prevents this proteolysis. The N-terminal domain of APE1 and its acetylation are required for modulation of the expression of hundreds of genes. Importantly, we found that AcAPE1 is essential for sustained cell proliferation. Together, our study demonstrates that increased acetylation levels of APE1 in tumor cells inhibit the limited N-terminal proteolysis of APE1 and thereby maintain the functions of APE1 to promote tumor cells' sustained proliferation and survival.

Original languageEnglish (US)
Pages (from-to)22590-22604
Number of pages15
JournalOncotarget
Volume7
Issue number16
DOIs
StatePublished - Apr 19 2016

Fingerprint

DNA-(Apurinic or Apyrimidinic Site) Lyase
Transcription Factor AP-1
Acetylation
Proteolysis
Cell Proliferation
Neoplasms
Lysine
DNA Damage
Serine Proteases

Keywords

  • Acetylation
  • APE1
  • Base excision repair
  • Proliferation
  • Proteolysis

ASJC Scopus subject areas

  • Oncology

Cite this

Bhakat, K. K., Sengupta, S., Adeniyi, V. F., Roychoudhury, S., Nath, S., Bellot, L. J., ... Luxon, B. A. (2016). Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation. Oncotarget, 7(16), 22590-22604. https://doi.org/10.18632/oncotarget.8026

Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation. / Bhakat, Kishor K.; Sengupta, Shiladitya; Adeniyi, Victor F.; Roychoudhury, Shrabasti; Nath, Somsubhra; Bellot, Larry J.; Feng, Dan; Mantha, Anil K.; Sinha, Mala; Qiu, Suimin; Luxon, Bruce A.

In: Oncotarget, Vol. 7, No. 16, 19.04.2016, p. 22590-22604.

Research output: Contribution to journalArticle

Bhakat, KK, Sengupta, S, Adeniyi, VF, Roychoudhury, S, Nath, S, Bellot, LJ, Feng, D, Mantha, AK, Sinha, M, Qiu, S & Luxon, BA 2016, 'Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation', Oncotarget, vol. 7, no. 16, pp. 22590-22604. https://doi.org/10.18632/oncotarget.8026
Bhakat KK, Sengupta S, Adeniyi VF, Roychoudhury S, Nath S, Bellot LJ et al. Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation. Oncotarget. 2016 Apr 19;7(16):22590-22604. https://doi.org/10.18632/oncotarget.8026
Bhakat, Kishor K. ; Sengupta, Shiladitya ; Adeniyi, Victor F. ; Roychoudhury, Shrabasti ; Nath, Somsubhra ; Bellot, Larry J. ; Feng, Dan ; Mantha, Anil K. ; Sinha, Mala ; Qiu, Suimin ; Luxon, Bruce A. / Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation. In: Oncotarget. 2016 ; Vol. 7, No. 16. pp. 22590-22604.
@article{ff496ec8649c45b7bf83250e7ee7d254,
title = "Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation",
abstract = "Mammalian apurinic/apyrimidinic (AP) endonuclease 1 (APE1), a ubiquitous and multifunctional protein, plays an essential role in the repair of both endogenous and drug-induced DNA damages in the genome. Unlike its E.coli counterpart Xth, mammalian APE1 has a unique N-terminal domain and possesses both DNA damage repair and transcriptional regulatory functions. Although the overexpression of APE1 in diverse cancer types and the association of APE1 expression with chemotherapy resistance and poor prognosis are well documented, the cellular and molecular mechanisms that alter APE1 functions during tumorigenesis are largely unknown. Here, we show the presence of full-length APE1 and N-terminal truncated isoforms of APE1 in tumor tissue samples of various cancer types. However, primary tumor tissue has higher levels of acetylated APE1 (AcAPE1) as well as full-length APE1 compared to adjacent non-tumor tissue. We found that APE1 is proteolytically cleaved by an unknown serine protease at its N-terminus following residue lysine (Lys) Lys6 and/or Lys7 and after Lys27 and Lys31 or Lys32. Acetylation of these Lys residues in APE1 prevents this proteolysis. The N-terminal domain of APE1 and its acetylation are required for modulation of the expression of hundreds of genes. Importantly, we found that AcAPE1 is essential for sustained cell proliferation. Together, our study demonstrates that increased acetylation levels of APE1 in tumor cells inhibit the limited N-terminal proteolysis of APE1 and thereby maintain the functions of APE1 to promote tumor cells' sustained proliferation and survival.",
keywords = "Acetylation, APE1, Base excision repair, Proliferation, Proteolysis",
author = "Bhakat, {Kishor K.} and Shiladitya Sengupta and Adeniyi, {Victor F.} and Shrabasti Roychoudhury and Somsubhra Nath and Bellot, {Larry J.} and Dan Feng and Mantha, {Anil K.} and Mala Sinha and Suimin Qiu and Luxon, {Bruce A.}",
year = "2016",
month = "4",
day = "19",
doi = "10.18632/oncotarget.8026",
language = "English (US)",
volume = "7",
pages = "22590--22604",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation

AU - Bhakat, Kishor K.

AU - Sengupta, Shiladitya

AU - Adeniyi, Victor F.

AU - Roychoudhury, Shrabasti

AU - Nath, Somsubhra

AU - Bellot, Larry J.

AU - Feng, Dan

AU - Mantha, Anil K.

AU - Sinha, Mala

AU - Qiu, Suimin

AU - Luxon, Bruce A.

PY - 2016/4/19

Y1 - 2016/4/19

N2 - Mammalian apurinic/apyrimidinic (AP) endonuclease 1 (APE1), a ubiquitous and multifunctional protein, plays an essential role in the repair of both endogenous and drug-induced DNA damages in the genome. Unlike its E.coli counterpart Xth, mammalian APE1 has a unique N-terminal domain and possesses both DNA damage repair and transcriptional regulatory functions. Although the overexpression of APE1 in diverse cancer types and the association of APE1 expression with chemotherapy resistance and poor prognosis are well documented, the cellular and molecular mechanisms that alter APE1 functions during tumorigenesis are largely unknown. Here, we show the presence of full-length APE1 and N-terminal truncated isoforms of APE1 in tumor tissue samples of various cancer types. However, primary tumor tissue has higher levels of acetylated APE1 (AcAPE1) as well as full-length APE1 compared to adjacent non-tumor tissue. We found that APE1 is proteolytically cleaved by an unknown serine protease at its N-terminus following residue lysine (Lys) Lys6 and/or Lys7 and after Lys27 and Lys31 or Lys32. Acetylation of these Lys residues in APE1 prevents this proteolysis. The N-terminal domain of APE1 and its acetylation are required for modulation of the expression of hundreds of genes. Importantly, we found that AcAPE1 is essential for sustained cell proliferation. Together, our study demonstrates that increased acetylation levels of APE1 in tumor cells inhibit the limited N-terminal proteolysis of APE1 and thereby maintain the functions of APE1 to promote tumor cells' sustained proliferation and survival.

AB - Mammalian apurinic/apyrimidinic (AP) endonuclease 1 (APE1), a ubiquitous and multifunctional protein, plays an essential role in the repair of both endogenous and drug-induced DNA damages in the genome. Unlike its E.coli counterpart Xth, mammalian APE1 has a unique N-terminal domain and possesses both DNA damage repair and transcriptional regulatory functions. Although the overexpression of APE1 in diverse cancer types and the association of APE1 expression with chemotherapy resistance and poor prognosis are well documented, the cellular and molecular mechanisms that alter APE1 functions during tumorigenesis are largely unknown. Here, we show the presence of full-length APE1 and N-terminal truncated isoforms of APE1 in tumor tissue samples of various cancer types. However, primary tumor tissue has higher levels of acetylated APE1 (AcAPE1) as well as full-length APE1 compared to adjacent non-tumor tissue. We found that APE1 is proteolytically cleaved by an unknown serine protease at its N-terminus following residue lysine (Lys) Lys6 and/or Lys7 and after Lys27 and Lys31 or Lys32. Acetylation of these Lys residues in APE1 prevents this proteolysis. The N-terminal domain of APE1 and its acetylation are required for modulation of the expression of hundreds of genes. Importantly, we found that AcAPE1 is essential for sustained cell proliferation. Together, our study demonstrates that increased acetylation levels of APE1 in tumor cells inhibit the limited N-terminal proteolysis of APE1 and thereby maintain the functions of APE1 to promote tumor cells' sustained proliferation and survival.

KW - Acetylation

KW - APE1

KW - Base excision repair

KW - Proliferation

KW - Proteolysis

UR - http://www.scopus.com/inward/record.url?scp=84965041791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965041791&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8026

DO - 10.18632/oncotarget.8026

M3 - Article

C2 - 26981776

AN - SCOPUS:84965041791

VL - 7

SP - 22590

EP - 22604

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -